As parallel advances in cancer biology and drug development continue to elevate the role of targeted therapies in oncology, the need for imaging biomarkers that systematically measure the biology associated with therapeutic intervention has become more urgent.
Although the molecular imaging community has a commitment to develop technologies to this end, few investigational radiotracers directly measure the biology of common oncogenic signaling pathways often addressed by targeted therapies. Visible progress has been achieved with a handful of radiotracers rationally designed to intercalate the pathobiology of prostate cancer, a molecularly heterogeneous disease nevertheless broadly defined by a fairly small repertoire of recurrent oncogenic lesions.
Written by:
Evans MJ. Are you the author?
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Reference: Cancer Discov. 2012 Nov;2(11):985-94.
doi: 10.1158/2159-8290.CD-12-0178
PubMed Abstract
PMID: 23043150
UroToday.com Investigative Urology Section
